ProBioGen announces that their proprietary vaccine production cell line AGE1.CR.pIX® has been successfully used to manufacture a viral vector product that has advanced into a randomized phase II clinical trial.

ProBioGen announces that their proprietary vaccine production cell line AGE1.CR.pIX® has been successfully used to manufacture a viral vector product that has advanced into a randomized phase II clinical trial. Nouscom has in-licensed ProBioGen's platform technology for the GMP production of a component of their neoantigen targeting cancer vaccine, Nous-209 targeting Microsatellite Instable High (MSI-H) solid tumors.

Nous-209 has been developed using the Nouscom's viral vector platform, which includes adenoviral and Modified Vaccinia Ankara (MVA) vectors, with MVA vectors manufactured using ProBioGen's AGE1.CR.pIX. This is Nouscom's third and most advanced clinical candidate benefitting from ProBioGen's production cell platform. The milestone represents a significant step towards bringing new, innovative products to patients and further underscores ProBioGen's commitment to supporting the development of life-changing treatments. Significant undisclosed milestone payments have been received by ProBioGen.

 

Back